Avastin has been rejected for use in treating advanced breast cancer on the NHS.
The decision by NICE came just days before US regulators will decide its fate in America.
NICE said Avastin (bevacizumab) offered “limited and uncertain benefit” for patients and did not lead to any significant extension of life.
It appraised Avastin in combination with a type of chemotherapy for treating breast cancer that has spread around the body. The guidance is now subject to an appeal.
The ruling came as the Food and Drug Administration (FDA) in the United States prepared to announce its decision, by 17 December, on the use of Avastin in breast cancer.
The FDA’s advisory panel in July voted in favour of revoking approval for the drug, declaring it did not offer a “clinically meaningful” benefit. European regulators are also reviewing the benefits of Avastin for breast cancer in light of fresh clinical data.
Avastin is licensed in the UK for bowel and kidney cancer but has not received approval from NICE for either of these diseases. It is also licensed for lung cancer.
NICE chief executive Sir Andrew Dillon said: “We know that it’s immensely important for breast cancer patients whose disease has spread to prolong their lives as much as possible.
“Unfortunately, we did not receive any evidence from the manufacturer to show that bevacizumab can significantly lengthen a patient’s life or, importantly, offer a better quality of life than existing treatments. Although the data seemed to show that the drug may slow the growth and spread of the cancer, the size of this effect varied between studies.
“Furthermore, it was extremely unclear that the benefits in terms of slowing tumour growth translated into benefits on overall survival, which is what really matters for patients.”